白细胞介素23抑制剂古塞奇尤单抗在银屑病治疗中的应用

doi:10.35541/cjd.20200712

Abstract

Abstract: 【Abstract】 Guselkumab is the first monoclonal antibody that selectively targets interleukin （IL）-23. Several randomized controlled clinical trials have demonstrated that it is highly effective and safe in the treatment of moderate to severe plaque psoriasis, and can significantly improve the quality of life of patients. This review summarizes the action mechanisms of IL-23 and guselkumab, as well as the application of guselkumab in the treatment of psoriasis.

Key words: Psoriasis, Interleukin-23, Guselkumab

Huang He, Zhang Xuejun. Application of the interleukin-23 inhibitor guselkumab in the treatment of psoriasis[J]. Chinese Journal of Dermatology, 2023, 56(2): 181-184.doi:10.35541/cjd.20200712

References ［23］

［1］	Di Cesare A, Di Meglio P, Nestle FO. The IL⁃23/Th17 axis in the immunopathogenesis of psoriasis［J］. J Invest Dermatol, 2009,129（6）:1339⁃1350. doi: 10.1038/jid.2009.59.
［2］	Tang H, Jin X, Li Y, et al. A large⁃scale screen for coding variants predisposing to psoriasis［J］. Nat Genet, 2014,46（1）:45⁃50. doi: 10.1038/ng.2827.
［3］	Girolomoni G, Strohal R, Puig L, et al. The role of IL⁃23 and the IL⁃23/TH 17 immune axis in the pathogenesis and treatment of psoriasis［J］. J Eur Acad Dermatol Venereol, 2017,31（10）:1616⁃1626. doi: 10.1111/jdv.14433.
［4］	Bovenschen HJ, van de Kerkhof PC, van Erp PE, et al. Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL⁃17A⁃producing cells and are found in lesional skin［J］. J Invest Dermatol, 2011,131（9）:1853⁃1860. doi: 10.1038/jid.2011.139.
［5］	Clark RA. Resident memory T cells in human health and disease［J］. Sci Transl Med, 2015,7（269）:269rv1. doi: 10.1126/scitranslmed.3010641.
［6］	Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti⁃interleukin⁃23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double⁃blinded, placebo⁃ and active comparator⁃controlled VOYAGE 1 trial［J］. J Am Acad Dermatol, 2017,76（3）:405⁃417. doi: 10.1016/j.jaad.2016.11.041.
［7］	Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti⁃interleukin⁃23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double⁃blind, placebo⁃ and active comparator⁃controlled VOYAGE 2 trial［J］. J Am Acad Dermatol, 2017,76（3）:418⁃431. doi: 10.1016/j.jaad.2016. 11.042.
［8］	Griffiths C, Papp KA, Song M, et al. Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate⁃to⁃severe psoriasis: results from VOYAGE 1［J］. J Dermatolog Treat, 2020:1⁃9［2021⁃02⁃19］. https://www.tandfonline.com/doi/full/10.1080/09546634.2020. 1782817. doi: 10.1080/09546634.2020.1782817.
［9］	Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate⁃to⁃severe psoriasis （ECLIPSE）: results from a phase 3, randomised controlled trial［J］. Lancet, 2019,394（10201）:831⁃839. doi: 10.1016/S0140⁃6736（19）31773⁃8.
［10］	Galluzzo M, Tofani L, Lombardo P, et al. Use of guselkumab for the treatment of moderate⁃to⁃severe plaque psoriasis: a 1 year real⁃life study［J］. J Clin Med, 2020,9（7）:2170. doi: 10.3390/jcm9072170.
［11］	Maliyar K, O′Toole A, Gooderham MJ. Long⁃term single center experience in treating plaque psoriasis with guselkumab［J］. J Cutan Med Surg, 2020,24（6）:588⁃595. doi: 10.1177/120347542 0932514.
［12］	Gordon KB, Armstrong AW, Foley P, et al. Guselkumab efficacy after withdrawal is associated with suppression of serum IL⁃23⁃regulated IL⁃17 and IL⁃22 in psoriasis: VOYAGE 2 study［J］. J Invest Dermatol, 2019,139（12）:2437⁃2446.e1. doi: 10.1016/j.jid. 2019.05.016.
［13］	Langley RG, Tsai TF, Flavin S, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double⁃blind, phase III NAVIGATE trial［J］. Br J Dermatol, 2018,178（1）:114⁃123. doi: 10.1111/bjd.15750.
［14］	Ruggiero A, Fabbrocini G, Cinelli E, et al. Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti⁃interleukin⁃17 treatment: a real⁃life 52⁃week retrospective study［J］. Dermatol Ther, 2021,34（1）:e14673. doi: 10.1111/dth.14673.
［15］	Reich K, Song M, Li S, et al. Consistent responses with guselkumab treatment in Asian and non⁃Asian patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2［J］. J Dermatol, 2019,46（12）:1141⁃1152. doi: 10.1111/1346⁃8138. 15109.
［16］	Ohtsuki M, Kubo H, Morishima H, et al. Guselkumab, an anti⁃interleukin⁃23 monoclonal antibody, for the treatment of moderate to severe plaque⁃type psoriasis in Japanese patients: efficacy and safety results from a phase 3, randomized, double⁃blind, placebo⁃controlled study［J］. J Dermatol, 2018,45（9）:1053⁃1062. doi: 10.1111/1346⁃8138.14504.
［17］	Yeremenko N, Paramarta JE, Baeten D. The interleukin⁃23/interleukin⁃17 immune axis as a promising new target in the treatment of spondyloarthritis［J］. Curr Opin Rheumatol, 2014,26（4）:361⁃370. doi: 10.1097/BOR.0000000000000069.
［18］	Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic⁃naive or had previously received TNFα inhibitor treatment （DISCOVER⁃1）: a double⁃blind, randomised, placebo⁃controlled phase 3 trial［J］. Lancet, 2020,395（10230）:1115⁃1125. doi: 10.1016/S0140⁃6736（20）30265⁃8.
［19］	Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic⁃naive patients with active psoriatic arthritis （DISCOVER⁃2）: a double⁃blind, randomised, placebo⁃controlled phase 3 trial［J］. Lancet, 2020,395（10230）:1126⁃1136. doi: 10.1016/S0140⁃6736（20）30263⁃4.
［20］	Sano S, Kubo H, Morishima H, et al. Guselkumab, a human interleukin⁃23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: efficacy and safety analyses of a 52⁃week, phase 3, multicenter, open⁃label study［J］. J Dermatol, 2018,45（5）:529⁃539. doi: 10.1111/1346⁃8138.14294.
［21］	Terui T, Kobayashi S, Okubo Y, et al. Efficacy and safety of guselkumab, an anti⁃interleukin 23 monoclonal antibody, for palmoplantar pustulosis: a randomized clinical trial［J］. JAMA Dermatol, 2018,154（3）:309⁃316. doi: 10.1001/jamadermatol. 2017.5937.
［22］	Reich K, Griffiths C, Gordon KB, et al. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials［J］. J Am Acad Dermatol, 2020,82（4）:936⁃945. doi: 10.1016/j.jaad.2019.11.040.
［23］	Puig L, Tsai TF, Bhutani T, et al. Safety in moderate⁃to⁃severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti⁃tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials［J］. J Eur Acad Dermatol Venereol, 2020,34（8）:1744⁃1749. doi: 10.1111/jdv.16460.

[1]	He Xie, Li Yuzhen. Targeting the JAK-STAT signaling pathway in the treatment of psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(3): 273-278.
[2]	Ruan Shifan, Zhang Peng, Lin Tingting, Luo Renwei, Bao Siyi, Xue Chenyao, Tong Zequn, Zhang Liangliang, Gong Ting, Ji Chao, . Correlations between psoriasis vulgaris and dyslipidemia [J]. Chinese Journal of Dermatology, 2023, 0(3): 20220322-e20220322.
[3]	Committee on Psoriasis, Chinese Society of Dermatology. Expert consensus on treat-to-target approach for the treatment of psoriasis with biological agents [J]. Chinese Journal of Dermatology, 2023, 56(3): 191-203.
[4]	Zhou Jian, Yu Chen, Wang Gang. Clinical efficacy and safety of secukinumab in the treatment of 13 cases of refractory localized pustular psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(3): 247-251.
[5]	Hu Kun, Yang Jing, Wang Qiaolin, Chen Junchen, Zhang Mi, Zhu Wu, Zhang Bin, Dou Guanshen, Wendong Chen, Kuang Yehong. Real-world short-term treatment effects of Ixekizumab in Chinese patients with psoriasis: a single-center retrospective study [J]. Chinese Journal of Dermatology, 2023, 56(3): 210-215.
[6]	Chen Lianghong, Sun Yan, Wang Jingyu, Wu Yan. Benvitimod for the treatment of dermatoses [J]. Chinese Journal of Dermatology, 2023, 0(2): 20210875-e20210875.
[7]	Yang Qi, Zheng Jie. Effect of biologics on cardiovascular comorbidities of psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(2): 165-169.
[8]	Wang Zhaoyang, Xiang Xin, Chen Yunliu, Miao Chaoyang, Zhao Xinrong, Zhang Zhenhua, Liu Yuanxiang, Ma Lin, Xu Zigang. Comparison of efficacy and safety of biologics versus methotrexate in the treatment of severe pediatric plaque psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(2): 112-117.
[9]	Yang Ying, Guo Qing, Hou Suchun, Min Xue, Tian Jiabin, Qiao Zhuhui, Lin Jialin, Wang Xiaofei, Wu Lantuya, Zhang Zhenying, Li Zhengfeng, Wang Bin, Liu Xiaoming. COVID-19 vaccination status and its impact on psoriatic lesions in patients with psoriasis treated with biologics: a single-center cross-sectional study [J]. Chinese Journal of Dermatology, 2023, 56(1): 59-63.
[10]	Zhou Xue, Yu Zengyang, Chen Youdong, Guo Chunyuan, Yu Qian, Hu Yifan, Yao Lingling, Shi Yuling, . Tumor necrosis factor α-mediated low expression of fatty acid desaturase 2 in psoriasis [J]. Chinese Journal of Dermatology, 2022, 55(9): 752-758.
[11]	Yao Lingling, Yu Zengyang, Guo Chunyuan, Zhou Jing, Cui Lian, Yu Qian, Yu Yingyuan, Zhou Xue, Cai Jiangluyi, Shi Yuling, . Changes in circadian gene cryptochrome 2 expression in mouse models of psoriasis and HaCaT cells and their underlying mechanisms [J]. Chinese Journal of Dermatology, 2022, 55(9): 759-766.
[12]	Yu Chen, Wang Gang. Small-molecule targeted agents: new choices for the treatment of psoriasis [J]. Chinese Journal of Dermatology, 2022, 55(9): 747-751.
[13]	Sun Jie, Wang Rui, Li Chengxin. Tumor necrosis factor-α inhibitor?induced psoriasis [J]. Chinese Journal of Dermatology, 2022, 55(9): 821-824.
[14]	Liu Jin, Shen Zhengyu. Epigenetic regulation in psoriasis [J]. Chinese Journal of Dermatology, 2022, 55(9): 825-829.
[15]	Zheng Jiayuan, Yu Bingqian, Chen Xianxia, Luo Zhicheng. Characteristics of pruritus in adult patients with psoriasis vulgaris and its effect on quality of life [J]. Chinese Journal of Dermatology, 2022, 55(9): 790-794.

Application of the interleukin-23 inhibitor guselkumab in the treatment of psoriasis

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［23］

Related Articles 15

Metrics

Comments

Recommended 10